TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05986357

Intervention type: DIAGNOSTIC_TEST
Intervention: maternal serum C reactive protein
Description: maternal serum high sensitivity C reactive protein

Intervention type: DIAGNOSTIC_TEST
Intervention: maternal serum C reactive protein
Description: maternal serum high sensitivity C reactive protein

Intervention type: DIAGNOSTIC_TEST
Intervention: total leucocytic count levels
Description: total leucocytic count levels

Intervention type: DIAGNOSTIC_TEST
Intervention: total leucocytic count levels
Description: total leucocytic count levels

Intervention type: DIAGNOSTIC_TEST
Intervention: differential leucocytic count levels
Description: differential leucocytic count levels

Intervention type: DIAGNOSTIC_TEST
Intervention: differential leucocytic count levels
Description: differential leucocytic count levels
Study: NCT04408144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10mg Oral Tablet
Description: oral 10mg dydrogesterone (Duphaston) 2 times daily
Study: NCT05315739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive transcutaneous vagus nerve stimulation (tVNS)
Description: tVNS delivers an electrical current to the cervical branch of the vagus nerve. Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2) are performed. The two periods are separated by a 2 weeks wash-out period.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vagus nerve stimulation
Description: The sham device produces a slight vibrating sound, but does not produce an electical current and hence, does not activate the vagus nerve.~Four minutes of bilateral stimulation 4 times per day for 7 days (period 1) and 2 times per day for 8 weeks (period 2). The two periods are separated by a 2 weeks wash-out period.
Study: NCT06381193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: oral, daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: oral, daily
Study: NCT05033834

Intervention type: OTHER
Intervention: covid-19 vaccines registered in Egypt
Description: Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine

Intervention type: OTHER
Intervention: covid-19 vaccines registered in Egypt
Description: Astra Zeneka vaccine, Sinopharm vaccine, Sinovac vaccine, Jonson and Jonson vaccine, Spotnic V vaccine
Study: NCT05098886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/1000mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210 10/1000mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/1000mg
Description: single dose administration (one tablet once a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5210-R 10/1000mg
Description: single dose administration (one tablet once a day)
Study: NCT05016063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: recommendation: 30mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytoxan
Description: recommendation: 300-500mg/m2 (D-5\~D-3),determined by tumor burden at baseline.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dual CD33-CLL1 CAR-T cells
Description: CD33-CLL1 CAR-T infusion (starting at dose level 1 \[DL1\]: 0.5 x 106 transduced CAR-T cells/kg) on Day 0.
Study: NCT06302686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: engAGE system
Description: The experimental group use the engAGE system at both healthcare organization and home. At the healthcare organization, the subject interacts with Pepper robot. The interaction is supervised by the formal caregivers and includes the following activities: dialoguing with the robot, storytelling, drama play, cognitive and physical games. This interaction is planned to last about 1 hour twice a week for 6 months. At home, the older user interacts with the tablet supervised by the informal caregiver. The user plays cognitive and physical games installed on MEMAS app. This activity is performed for 0.5 hour, every day for 6 months. Throughout the whole period of experimentation, the older user wears the smartwatch that measures his/her physiological parameters and the steps. Any activity performed by the seniors is assigned by formal caregiver and can be personalized taking into account the user's abilities, lifestyle, and social interactions.

Intervention type: OTHER
Group type: OTHER
Intervention: Group practicing with only the support of a booklet
Description: To the control group will be given a booklet containing information and activities on well-being to do at home.
Study: NCT05940909

Intervention type: DRUG
Group type: OTHER
Intervention: Perindopril/Indapamide/Amlodipine 8 mg/2.5 mg/10 mg tablet / Triplixam® 10 mg/2.5 mg/10 mg tablet
Description: Perindopril/Indapamide/Amlodipine is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 8 mg of perindopril erbumine, 2.5 mg of indapamide and 10 mg of amlodipine.~Triplixam® is manufactured by Les Laboratoires Servier Industrie, France. Each tablet contains 10 mg of perindopril arginine, 2.5 mg of indapamide and 10 mg of amlodipine.
Study: NCT06381193

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic + Prebiotic
Description: oral, daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, daily
Study: NCT05518890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Only
Description: Participants caloric intake will be reduced by 5000kcal per week over 4 weeks
Study: NCT06251011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 1. Physical therapy training via video call~2. An advise and a leaflet for cardiopulmonary rehabilitation
Study: NCT05443139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-being online
Description: Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Well-being online
Description: Multi component Intervention composed 10 sessions following a structure based on Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), Positive Psychology (PP), Mindfulness and Behavioral Activation Therapy (BAT).
Study: NCT00678678

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incentive Spirometry - RESPIRON
Description: Device that stimulates the deep breathing, flow-oriented

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kit Epap®:
Description: Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
Study: NCT05934669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Midazolam
Description: Using a computer-generated randomization schedule by the research pharmacist, all 90 subjects will be divided into 3 even groups to receive either medication A (intranasal Midazolam), B (intranasal Dexmedetomidine), or C (intranasal Ketamine). Based on the randomization schedule, the pharmacist will dispense medication A, B, or C to the chronological number provided in the order. The total amount of the medication will be based on the patient's charted weight. Small volumes of less than 1ml per nostril are preferred for reliable absorption; therefore, the medication will be dispensed in a 1ml syringe and the barrel of the syringe will be covered by the pharmacist. All the syringes sent from the pharmacy will appear the same, regardless of the volume of the medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: See above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: See above
Study: NCT05699473

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF glucosamine salt
Description: Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) glucosamine salt

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF calcium salt 1
Description: Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 1

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-MTHF calcium salt 2
Description: Active form of folate defined as (6S) 5-methyltetrahydrofolate (5-MTHF) calcium salt, crystal form 2
Study: NCT05518890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise
Description: Participants caloric intake will be reduced by 5000kcal per week over 4 weeks. Participants will also be asked to perform 5x30 minute cycling exercise sessions at home. Each week the intensity of exercise will be increased (week 1 = RPE 12, week 2 = RPE 13, week 3 = RPE 14, week 4 = RPE 15)
Study: NCT04711980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mudan granule
Description: Mudan granule,a traditional Chinese medicine formula,consists of nine Chinese herbs.~Other: Standard medical care.Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Granule(Placebo) is in accordance with Mudan granule in appearance, colour, taste.~Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
Study: NCT04775745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168
Description: For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-168
Description: For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.
Study: NCT04700774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Description: Brief Behavioral Activation Treatment with and without motor enhancement. All patients will receive 10 online video sessions. BA focuses on increasing overt behaviors to bring patients into contact with reinforcing environmental contingencies and corresponding improvements in thoughts, mood, and quality of life (Hopko, Lejuez, et al., 2003). BA follows the basic behavioral principles of extinction, shaping, fading, and in vivo exposure (Hopko \& Lejuez, 2007; Lejuez et al., 2001, 2011). In the mBA condition only a) patients will be introduced to the idea that the motor system can be used in the service of action initiation and will receive an audio recording with motor manipulations to assist in action initiation and b) the therapist will conduct imaginary behavioral activation and - in session - complete questionnaires identical to those in the experiment before and after the bodily instructions presented in the treatment.
Study: NCT06046846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Asensei app
Description: The study will compare the delivery of a prehabilitation programme via a mHealth application against standard preoperative care for patients undergoing surgery for oesophago-gastric cancer
Study: NCT05824143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darigabat
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Oral tablets
Study: NCT06121128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: The POWERbreathe™ Plus: an Inspiratory Muscle Training device (IMT) with adjustable resistance.~Intervention lasts 4 weeks, with a frequency of 6 days/week, 2 series of 30 inspirations in the morning and evening.~Resistance based on 60% of the Pressure Maximal Inspiratory (PMI). Progressive increase in resistance every week.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Normal Breathing
Description: No IMT performed

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Normal Breathing
Description: No IMT performed
Study: NCT05223894

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hiPSC-CM therapy
Description: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 100 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Coronary artery bypass grafting surgery only.
Study: NCT05860647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation
Description: MagVenture TMS Therapy with theta burst stimulation. Resting motor threshold: 80%; Number of pulses per session: 1200 pulses; Inter-train interval: 8 seconds; Pulse frequency in burst: 50 Hertz
Study: NCT05798052

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological stressors added to simulated clinical scenarios.
Description: In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychological stressors added to simulated clinical scenarios.
Description: In both low and high stress scenario versions, the underlying mechanism of disease or injury will be identical, as will be the expected clinical management of the situation. Known stressors9,10 will be added to the scenarios, ensuring ecological validity (stressors that occur in real life). The stressors will include a) socio-evaluative stressors (presence of other with ability to negatively judge); b) increases in the severity of the situation (unstable patient); c) increases in the stakes (e.g. woman in early stages of pregnancy), d) noise, as well as e) unexpected brief complications (e.g. brief equipment challenge).
Study: NCT06548321

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description:  The ESTW machine is turned on and the instrument, or shockwave gun, is pressed against the affected area. Rapid impulses are then delivered to the patient. Treatment typically lasts between 5 and 15 minutes. While this treatment can be uncomfortable for some, most do not experience any pain.~Once treatment is completed, patients should do their best to physical activity... higher levels of energy Shockwaves into deeper tissue locations... ESWT therapies can help treat neurological disorders like multiple sclerosis and the effects of stroke.
Study: NCT05750992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical TAP block
Description: performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally by the surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: US guided TAP block
Description: performed by 40 ml of 0.25% bupivacaine (10 ml 0.5% bupivacaine bilaterally diluted with 10cc normal saline and 100 μg of fentanyl), the total volume was divided equally and administered bilaterally.
Study: NCT05288582

Intervention type: DEVICE
Group type: OTHER
Intervention: NovaTears
Description: Over-the-counter eye drop
Study: NCT04397484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Levobupivacaine
Description: The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Xylocaine with adrenaline 1:200,000
Description: The plane where the sciatic nerve bifurcates will at first be identified by utlrasound. 22-gauge insulated nerve block needle will be inserted in the short axis (out-of-plane) of the ultrasound transducer, and advanced toward the cleavage between the common peroneal nerve and the tibial nerve, which is the easiest location for needle access into subparaneural compartment.Once the needle tip enters the subparaneural compartment 2-3 ml of normal saline will be injected (hydro-distension) to create a halo around both the common peroneal nerve and tibial nerve distally and the sciatic nerve proximally. The needle is then redirected to place its tip into the paraneural sheath of the common peroneal and tibial nerve through the same skin puncture and 15ml of study drug will be injected at each site (total 30ml).
Study: NCT06405971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Patients in the drug group took one tablet of metformin hydrochloride enteric capsule orally each day after breakfast and dinner, and the dose of each tablet was 250mg.
Study: NCT06099145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hephaï
Description: Used of the HEPHAI medical device as a tool to improve the delivery of inhaled treatments for asthma and COPD
Study: NCT05946434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Group
Description: Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape Group
Description: Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end kinesio taping will be performed at knee joint for inhibition.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Tape Group
Description: Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Tape Group
Description: Physiotherapy Protocol Followed:~* Hot pack and TENS application for 10 minutes.~* Knee isometric exercises by placing roller beneath knee joint and pressing it by keeping leg straight and holding it for 10-15 seconds with 10 repetitions.~* Stretching of hamstrings and gastrocnemius muscles, maintaining stretch for 20 seconds and 7 repetitions should be performed.~* Tibio-femoral glides and patellar mobilizations will be performed.~* At the end rigid tape will be applied on knee joint to provide stability.~Same procedure will be followed in all follow ups at day 1, day 14 and day 28
Study: NCT06092047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UTAA09 cells for infusion
Description: Intravenous injection, dosage:1-10×10\^8 CAR+ γδT cells, Cell concentration: 2×10\^7 cells/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2/day×4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1000 mg/m\^2/day×3 days